ProfoundBio, a clinical-stage biotechnology company focused on novel antibody-based therapeutics for cancer patients, has successfully raised $112 million in its Series B funding round.
The funding round was led by Ally Bridge Group, with participation from new investors including Nextech Invest, T. Rowe Price Associates, Inc., Janus Henderson Investors, RA Capital Management, and others.
Existing investors Lilly Asia Ventures (LAV) and LYFE Capital also continued their support.
Advancing Clinical-Stage ADC Pipeline
The company plans to utilize the funds to advance the development of its differentiated clinical-stage Antibody-Drug Conjugate (ADC) pipeline.
This includes supporting the planned pivotal trial of rinatabart sesutecan (Rina-S), one of its lead drug candidates.
Focus on Novel Therapeutics for Cancer
ProfoundBio, led by CEO Baiteng Zhao and COO/CFO Erin Lavelle, is dedicated to developing innovative treatments for cancer patients.
The company’s pipeline includes multiple ADC drug candidates targeting both solid tumors and hematological malignancies.
Among these are rinatabart sesutecan (Rina-S; PRO1184), PRO1160 targeting CD70, PRO1107 targeting PTK7, and PRO1286, a bispecific ADC targeting two solid tumor antigens.
Strengthening Leadership and Board
In addition to the funding, ProfoundBio has enhanced its board of directors with the appointment of Andrew Lam from Ally Bridge Group.
The company has also added two independent directors, Eric Dobmeier and Enoch Kariuki, who bring valuable experience in biotechnology and investment.
They join existing board members Baiteng Zhao, Lynn Yang (HongShan), and Josh Jin (LAV).
ProfoundBio’s successful funding round underscores the growing interest and support for innovative cancer therapeutics, particularly in the field of ADCs.
The company’s commitment to advancing its pipeline and strengthening its leadership team positions it well for future growth and development in the fight against cancer.
Share on Facebook «||»
Share on Twitter «||»
Share on Reddit «||»
Share on LinkedIn
Prota Therapeutics Secures Substantial Funding Led by SPRIM Global Investments, Propelling Accelerated Phase 3 Clinical Investigation for Revolutionary PRT120 Oral Therapy Targeting Peanut Allergy: Major Funding Round for Prota Therapeutics Led by SPRIM Global Investments In a significant development, Prota Therapeutics, a biotech company led by Executive Chairman Kelly...
BD Life Sciences – Biosciences Conducts a User Group Conference “Advances in Clinical Flow Cytometry (ACFC) in the Commemoration of World Cancer Day”: To commemorate World Cancer Day observed each year on 4th February, Life Sciences-Biosciences, a segment of BD (Becton, Dickinson and Company) organized a virtual clinical...
Lyndra Therapeutics Secures $101Million in Series E Funding for Advancement of Long-Acting Oral Therapies: Clinical-stage biopharmaceutical company Lyndra Therapeutics has successfully raised $210 million in a Series E funding round, marking a significant milestone for the organization. The funding...
ProducePay Secures $38M in Series D Funding Led by Syngenta Group Ventures: In a recent funding round, agricultural technology company ProducePay has secured substantial investment led by Syngenta Group Ventures. This round also saw participation from new...
Legal Tech Pioneer Proof Secures $30.4M Series B Funding Round Led by Long Ridge Equity Partners: A recent funding round spearheaded by Long Ridge Equity Partners has successfully raised capital for Proof, a litigation services marketplace. This financial boost also saw...
Thentia Secures $38M Series B Extension Funding Led by Key Investors: Venture Funding Led by Key Investors A recent funding round spearheaded by First Ascent Ventures, Spring Mountain Capital, BDC Capital, and Espresso Capital has marked...
Artificial Labs Secures £8M in Series A+ Funding Led by Augmentum Fintech for Expansion and Product Development: Introduction: Artificial Labs, a leading insurtech company, secures £8 million in Series A+ funding, spearheaded by Augmentum Fintech. The funding aims to drive the company’s...
Apollo Therapeutics completes Series C with a $33.5M second close, reaching a total of $260M: Funding Boost for Apollo Therapeutics Apollo Therapeutics recently secured a substantial round of funding, totaling $260M, marking a significant milestone for the company. Spearheaded by...
NextPoint Therapeutics’ Series B Financing Hits $122.5 Million Mark, Driven by Catalio Capital Management: In a significant financial move, NextPoint Therapeutics has successfully raised $42.5 million in its latest funding round, bringing the total Series B financing to an...
Remix Therapeutics Secures Substantial Investment to Pave Way for RNA-Targeted Therapies: Remix Therapeutics Secures Significant Investment for RNA Treatment Advancements Biotechnology company Remix Therapeutics has secured a substantial investment round led by The Column Group, along...
